Scientists are eagerly anticipating pozelimab, a novel antibody showing promising results in preliminary clinical trials . This compound targets aggregated tau – a key hallmark of the neurodegenerative https://socialmediainuk.com/story27512107/pozelimab-a-new-breakthrough-for-the-disease